COVID debates are more than just science vs. misinformation
During the time before vaccines, a friend of mine told me he was traveling home for Christmas despite the pandemic but would not visit his 93-year-old grandmother. A perfectly reasonable position: She was in a high-risk group for COVID-19 based on age. No one would want to make their loved ones sick.
And yet, how many more Christmases and how many more visits can a 93-year-old grandmother be expected to enjoy? Actuarially speaking, not visiting her may mean never seeing her again. Perhaps, if she is up for the risk, you should be too? It would also still be understandable for you to not want to bear the responsibility of making her potentially fatally ill, even if she extended the invitation.
The above dilemma is a common one in the COVID era and it does not come down to science versus misinformation. People can reach different conclusions about what the correct answer is while looking at the same data. Many of the conflicts we have over the pandemic are not about having different views of what the science says, although that certainly does happen as well. The biggest debates involve trade-offs and differences in values or priorities.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Those debates can be informed by the science. But science cannot resolve them. Science can help understanding of the risk of exposing my grandmother to COVID. It can also tell me what a normal human lifespan is. But it cannot tell me what the right answer is in terms of visiting her, at least in a way that is acceptable to everyone.
Some of the differences of opinion over business restrictions during the pandemic or mask mandates or other public policies may stem from how seriously one takes the virus. But often, they come down to valuing certain cost-benefit analyses differently. The government, of course, has to try to make these decisions based on the common good. But individual policymakers will differ, sometimes based even on their own areas of expertise.
None of this is to say there isn't a great deal of misinformation circulating, especially about the vaccines. But believing in science is not the same as believing it resolves all questions in life.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
W. James Antle III is the politics editor of the Washington Examiner, the former editor of The American Conservative, and author of Devouring Freedom: Can Big Government Ever Be Stopped?.
-
The challenge facing Syria's Alawites
Under The Radar Minority sect that was favoured under Assad now fears for its future
By Chas Newkey-Burden, The Week UK Published
-
Will Biden's AI rules keep the genie in the bottle?
Talking Points A new blow in the race for 'geopolitical superiority'
By Joel Mathis, The Week US Published
-
Israel and Hamas reach long awaited Gaza ceasefire
The Explainer After more than a year of violence that has left tens of thousands dead and pushed the Middle East toward broader regional war, negotiators say an end is in sight
By Rafi Schwartz, The Week US Published
-
Unprepared for a pandemic
Opinion What happens if bird flu evolves to spread among humans?
By William Falk Published
-
Palestinians and pro-Palestine allies brace for Trump
TALKING POINTS After a year of protests, crackdowns, and 'Uncommitted' electoral activism, Palestinian activists are rethinking their tactics ahead of another Trump administration
By Rafi Schwartz, The Week US Published
-
Ukraine hints at end to 'hot war' with Russia in 2025
Talking Points Could the new year see an end to the worst European violence of the 21st Century?
By Rafi Schwartz, The Week US Published
-
Is the US becoming an oligarchy?
Talking Points How much power do billionaires like Elon Musk really have?
By Joel Mathis, The Week US Published
-
Jay Bhattacharya: another Covid-19 critic goes to Washington
In the Spotlight Trump picks a prominent pandemic skeptic to lead the National Institutes of Health
By David Faris Published
-
What is Mitch McConnell's legacy?
Talking Point Moving on after a record-setting run as Senate GOP leader
By Joel Mathis, The Week US Published
-
Who will win the coming US-China trade war?
Talking Points Trump's election makes a tariff battle likely
By Joel Mathis, The Week US Published
-
The political latitude of Musk's cost-cutting task force
Talking Points A $2 trillion goal. And big obstacles in the way.
By Joel Mathis, The Week US Published